Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01902953 · ClinicalTrials.gov registry record · Phase 2

Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)

A Phase 2 study, sponsored by Maimonides Medical Center.

Completed
Registry status
Phase 2
Development phase
16
Enrollment target

NCT01902953 is a Phase 2 study that has completed, run by Maimonides Medical Center. The registered enrollment target is 16 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01902953, a Phase 2 study, has completed, sponsored by Maimonides Medical Center.

COMPLETED
Registry status
Phase 2
Development phase
16 participants
Enrollment target

Study Summary

45 patients undergoing a colon (large bowel/intestine)removal operation for the diagnosis of colon cancer will be included in this study. During colon operation the affected portion of the colon is removed. In addition, lymph nodes are included in the specimen and evaluated by a pathologist. Analysis of the lymph nodes in the specimen are important because this is an important aspect of determining the stage of the cancer. Once the standard technique is used for the colon removal operation and the specimen is removed it will be injected with two drugs to help identify the lymph nodes. One is a blue dye and the other a radiotracer. The colon and ALL of the lymph nodes will then be sent for the standard pathologic evaluation. The patient themselves will never be injected with these drugs being used for research. Following the standard lymph node evaluation, an additional pathologist at an outside research facility will further examine the lymph nodes in the specimen using more in depth techniques which are above and beyond the standard of care. The results of all the pathologic tests will be conveyed to the surgeon of record to help in their decision making regarding further treatment. The study hypothesis is that radiotracer will be at least as effective as blue dye in identifying the lymph nodes most likely to harbor cancer cells (sentinel nodes). Once identified, these sentinel nodes can then undergo a more in depth review leading to improved staging of colorectal cancer and more accurate treatment.

Interventions

  • DRUG Lymphoseek and VBD Sln dissection

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2013-03
Est. Completion 2016-06
Phase Phase 2

Sponsor

Maimonides Medical Center

39 total trials

What the Registry Record Tells You About NCT01902953

The ClinicalTrials.gov registry entry for NCT01902953 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Maimonides Medical Center, which has 39 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Lymphoseek and VBD Sln dissection is the first listed.

NCT01902953 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01902953 about?

NCT01902953 is a clinical study titled "Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)". 45 patients undergoing a colon (large bowel/intestine)removal operation for the diagnosis of colon cancer will be included in this study. During colon operation the affected portion of the colon is removed. In addition, lymph nodes are included in the specimen and evaluated by a pathologist. Analysi...

What is the current status of trial NCT01902953?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2013-03. Estimated completion is 2016-06.

What interventions are being tested in trial NCT01902953?

The interventions under investigation include: Lymphoseek and VBD Sln dissection (DRUG).

Who is sponsoring clinical trial NCT01902953?

This trial is sponsored by Maimonides Medical Center, which has 39 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.